A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

PHASE2CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

March 12, 2014

Primary Completion Date

October 22, 2024

Study Completion Date

October 22, 2024

Conditions
Microsatellite Unstable Colorectal CancerMicrosatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal CancerMismatch Repair Deficient Colorectal Cancer
Interventions
DRUG

Ipilimumab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Cobimetinib

Specified dose on specified days

DRUG

Daratumumab

Specified dose on specified days

DRUG

BMS-986016

Specified dose on specified days

Trial Locations (32)

0

Local Institution - 0022, Dublin

Local Institution - 0023, Dublin

Local Institution - 0033, Galway

1000

Local Institution - 0019, Brussels

1090

Local Institution - 0018, Brussels

2145

Local Institution - 0040, Westmead

3000

Local Institution - 0037, Melbourne

Local Institution - 0020, Leuven

4215

Local Institution - 0039, Southport

10060

Local Institution - 0030, Candiolo, Torino

15232

Local Institution - 0013, Pittsburgh

18103

Local Institution - 0041, Allentown

27103

Local Institution - 0029, Winston-Salem

27710

Local Institution - 0024, Durham

28009

Local Institution - 0012, Madrid

28050

Local Institution - 0010, Madrid

30322

Local Institution - 0008, Atlanta

37232

Local Institution - 0006, Nashville

41013

Local Institution - 0011, Seville

41124

Local Institution - 0035, Modena

55407

Local Institution - 0034, Minneapolis

75571

Local Institution - 0025, Paris

85234

Local Institution - 0028, Gilbert

90033

Local Institution - 0004, Los Angeles

94115

Local Institution - 0001, San Francisco

97213

Local Institution - 0005, Portland

02114

Local Institution - 0002, Boston

Local Institution - 0036, Boston

77030-4009

Local Institution - 0003, Houston

T6G 1Z2

Local Institution - 0027, Edmonton

M5G 1X5

Local Institution - 0016, Toronto

Padova

Local Institution - 0032, Padua

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY